TORONTO, Feb. 24,
2025 /PRNewswire/ -- In today's era of rapid
technological advancement, the deep integration of artificial
intelligence and the medical field is bringing unprecedented hope
to human health. Among these advancements, targeted therapy, a
cornerstone of precision medicine, is gradually reshaping the
treatment landscape for cancer and other major diseases with its
unique advantages. Visionary Holdings (Nasdaq Stock Code: GV), a
globally influential multinational corporation, stands at the
forefront of this medical revolution, leading targeted therapy to
new heights.
Targeted therapy, an innovative treatment based on molecular
biology, precisely targets diseased cells while sparing healthy
ones, significantly improving treatment efficacy and reducing the
side effects associated with traditional radiotherapy and
chemotherapy. Drugs like Erlotinib for EGFR-mutated non-small cell
lung cancer and Herceptin for HER2-positive breast cancer have
markedly improved patient survival rates. With the progress of
precision medicine, targeted therapy is not only excelling in
cancer treatment but is also expanding into areas such as
neurodegenerative diseases and autoimmune disorders. According to
McKinsey Global Institute, the global biopharmaceutical market is
projected to exceed $1.5 trillion by
2030, with the precision medicine sector expected to grow at a
compound annual growth rate (CAGR) of over 10%, indicating a highly
promising future for targeted therapy.
Visionary Holdings has keenly recognized the immense potential
of the biopharmaceutical field and has actively invested in
cutting-edge areas such as tumor-targeted therapy, gene sequencing,
AI-assisted drug development, and liquid biopsy. The company is
focused on advancing next-generation immunotherapies, gene editing,
and precision oncology, enhancing biomarker detection and liquid
biopsy technologies, and leveraging AI to accelerate drug
development. It has also successfully developed rapid at-home
testing technologies for cervical and colorectal cancers,
increasing cancer screening coverage and providing significant
convenience for early diagnosis.
In practical terms, Visionary Holdings has driven substantial
breakthroughs in targeted therapy through a series of strategic
investments and collaborations. The company has made strategic
investments in leading biotech firms to co-develop third-generation
EGFR inhibitors aimed at overcoming drug resistance in non-small
cell lung cancer patients. This drug is currently in global
clinical trials and has garnered widespread attention.
Additionally, Visionary Holdings has partnered with top gene
sequencing companies to develop liquid biopsy technologies,
enabling real-time monitoring of cancer progression through
non-invasive blood tests, making treatments more precise and
efficient.
Furthermore, Visionary Holdings has collaborated with numerous
global biotech leaders, AI pharmaceutical giants, and medical
research institutions to pioneer innovative projects. In targeted
drug development, the company is focusing on specific gene
mutations such as HER2, BRAF, and KRAS to develop next-generation
anticancer drugs. By utilizing AI drug discovery technologies, deep
learning algorithms are employed to analyze protein structures,
significantly speeding up drug screening and optimization. Its
global clinical trial network spans North
America, Europe, and
Asia, accelerating the
time-to-market for new drugs and benefiting more patients.
Looking ahead, the combination of targeted therapy and
immunotherapy will become a trend, and AI will be deeply integrated
into precision medicine, substantially shortening drug development
cycles and reducing costs. The application scope of targeted
therapy will continue to expand, offering hope to patients with a
wider range of diseases. Visionary Holdings will continue to
leverage its cutting-edge technology, strategic vision, and global
collaboration network to deepen its commitment to targeted therapy
and precision medicine. The company is dedicated to developing
next-generation targeted drugs, improving global patient access to
advanced treatments, leading the new era of precision medicine, and
writing a new chapter in the pursuit of human health.
For more information, please contact:
Visionary Holdings Inc.
Investor Relations Department
Email: ir@farvision.ca
View original
content:https://www.prnewswire.com/news-releases/visionary-holdings-navigates-a-new-era-of-precision-medicine-achieving-major-breakthroughs-in-targeted-therapy-302382425.html
SOURCE Visionary Holdings Inc.
